The global autologous cell therapy market size was exhibited at USD 6.80 billion in 2023 and is projected to hit around USD 41.41 billion by 2033, growing at a CAGR of 19.8% during the forecast period 2024 to 2033.
Key Takeaways:
Autologous Cell Therapy Market Report Scope
Report Coverage | Details |
Market Size in 2024 | USD 8.15 Billion |
Market Size by 2033 | USD 41.41 Billion |
Growth Rate From 2024 to 2033 | CAGR of 19.8% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Source, Application, End-use, Region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Key Companies Profiled | BrainStorm Cell Therapeutics; Holostem Terapie Avanzate S.R.L; Pharmicell Co. Inc; Opexa Therapeutics; Caladrius Biosciences Inc; U.S. Stem Cell Inc; Lonza; Bristol Myers Squibb; Novartis; Autolus therapeutics; Tego Science; Corning Incorporated; Bio Elpida; Vericel Corporation; Catalent, Inc; Sartorius AG . |
Some of the key factors driving the market growth include numerous immunological advantages, a rise in the proportion of the geriatric population across the globe, and a reduced risk of autologous cell therapy rejection. Autologous cell therapy is widely used in a range of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and others.
Due to COVID-19, the autologous cell therapy market was significantly affected by the less inflow of patients due to restrictions on movement imposed by various governments across the world. Alternatively, during the initial phase of the COVID-19 outbreak, the majority of clinical trials were on hold however the post COVID-19 the hospitals and clinics have witnessed patient flow for clinical or cell therapy applications.
Segments Insights:
Source Insights
In terms of revenue, the bone marrow segment dominated the market with a share of over 42.9% in 2023. Based on sources, the autologous cell therapy market is segmented into bone marrow, epidermis, mesenchymal stem cells, haematopoietic stem cells, chondrocytes, and others. The bone marrow in autologous cell therapy is been successfully used to treat different diseases. It is one of the major sources used for cell therapy where the patient’s healthy stem cells are collected from the bone marrow or blood before treatment stored. Alternatively, autologous cell therapy with bone marrow provides certain benefits over a donor’s stem cells.
The mesenchymal stem cells segment is anticipated to witness the fastest growth over the forecast period owing to their preclinical and clinical applications in tissue regeneration to therapy for immune diseases. For instance, in March 2020, the Celltex Therapeutics Corporation announced that it has begun active discussions with the FDA regarding a study using of MSCs against COVID-19 symptoms. In addition, the company has researched the safety and efficiency of the use of MSCs for patients suffering from injuries, pain, and maladies associated with vascular, autoimmune, and other debilitating including inflammatory lung conditions, chronic obstructive pulmonary disease (COPD), and pneumonia.
Application Insights
In terms of revenue, the cancer segment dominated the market with a share of over 20.7% in 2023. Based on application, the market is segmented into cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and others. According to WHO (World Health Organization), cancer disease accounts for nearly 10 million deaths in 2020.
As per the American Cancer Society, in 2023, 1.9 million new cancer cases were diagnosed and 608,570 cancer deaths in the U.S. Autologous cell therapy is anticipated to find its major demand in cancer application with the growing burden of cases and demand for treatment and therapy. In August 2022, Anixa Biosciences mentioned that it has administered the first dose of its follicle-stimulating hormone receptor (FSHR)- targeted autologous cell therapy to an ovarian cancer patient in a Phase I trial.
End-use Insights
In terms of revenue, the hospitals & clinics segment dominated the market with a share of over 50.0% in 2023. Based on end use, the market is segmented into hospitals & clinics, ambulatory centers, academics & research, and others. The increasing burden of cancer, autoimmune diseases, cardiovascular diseases, and neurodegenerative disorders have led to the rising requirement for treatment and therapies.
The academics & research segment is anticipated to witness growth at a CAGR of 20.8% over the estimated timeframe. Autologous cell therapy is garnering an increasing amount of interest worldwide and is being extensively studied. It is an emerging field of science that uses the living cellular to treat and prevent disease. Academics and research mostly conduct research in bone marrow, epidermis, mesenchymal stem cells, haematopoietic stem cells, and chondrocytes. For instance, in October 2022, Allogene Therapeutics mentioned the new survey of the U.S academic institutes that specialized in the administration of CAR T, which discovered 82% of respondents agreed that CAR T therapies have assisted in the management of cancers.
Regional Insights
North America dominated the autologous cell therapy market with a revenue share of 45.0% in 2023. The market in this region is highly competitive since most of the major market players such as BrainStorm Cell Therapeutics, Bristol Myers Squibb is operating in this region. Furthermore, the growing burden of the geriatric population, numerous immunological advantages, and the reduced risk of autologous cell therapy rejection have created new growth opportunities for the autologous cell therapy Market.
Asia Pacific is anticipated to grow at the fastest CAGR of 20.0% over the forecast period owing to the rising burden of diseases, strong research activities in autologous cell therapies, the presence of a well-established biotechnology sector, developing healthcare facilities, and growing awareness for cell therapies. For instance, in November 2018, Atara Biotherapeutics announced the results of phase 1 clinical study carried out by the company’s collaboration at the University of Queensland and QIMR Berghofer Medical Research Institute. It describes findings in progressive multiple sclerosis patients which were treated with Atara’s autologous EBV-specific T-cell immunotherapy
Some of the prominent players in the Autologous cell therapy market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2023 to 2033. For this study, Nova one advisor, Inc. has segmented the global autologous cell therapy market.
Source
Application
End-use
By Region
Chapter 1 Report Scope and Objectives
1.1 Market Segmentation & Scope
1.2 Regional Scope
1.2.1 Estimates And Forecast Timeline
1.3 Objectives
1.3.1 Objective - 1
1.3.2 Objective - 2
1.3.3 Objective - 3
Chapter 2 Methodology
2.1 Research Methodology
2.2 Information Procurement
2.2.1 Purchased Database
2.2.2 Internal Database
2.2.3 Secondary Sources
2.2.4 Primary Research
2.3 Information Or Data Analysis
2.3.1 Data Analysis Models
2.4 Market Formulation & Validation
2.5 Model Details
2.5.1 Commodity Flow Analysis (Model 1)
2.5.2 Volume Price Analysis (Model 2)
2.6 List Of Secondary Sources
Chapter 3 Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.2.1 Source
3.2.2 Application
3.2.3 End Use
3.2.4 Region
3.3 Competitive Insights
3.4 Autologous Cell Therapy Market Outlook, 2021
Chapter 4 Market Variables, Trends & Scope
4.1 Market Lineage Outlook
4.1.1 Parent Market Outlook
4.1.2 Ancillary Market Outlook
4.2 Autologous Cell Therapy Market Dynamics
4.2.1 Market Driver Analysis
4.2.2 Market Restraint Analysis
4.3 Autologous Cell Therapy Market: Business Environment Analysis Tools
4.3.1 Porter’s Five Forces Analysis
4.3.1.1 Threat of new entrants
4.3.1.2 Bargaining power of suppliers
4.3.1.3 Bargaining power of buyers
4.3.1.4 Competitive rivalry
4.3.1.5 Threat of substitutes
4.3.2 Pestel Analysis
4.3.2.1 Political & Legal Landscape
4.3.2.2 Economic Landscape
4.3.2.3 Technological Landscape
4.4 Penetration & Growth Prospect Mapping
4.5 Impact Of Covid-19 On Autologous Cell Therapy Market
Chapter 5 Autologous Cell Therapy Market: Source Analysis
5.1 Autologous Cell Therapy Market Share Analysis, 2024 & 2033
5.2 Autologous Cell Therapy Market: Segment Dashboard:
5.3 Market Size & Forecasts And Trend Analyses, 2021 To 2033 For The Services Segment
5.3.1 Bone Marrow
5.3.1.1 Bone Marrow Market, 2021 - 2033
5.3.2 Epidermis
5.3.2.1 Epidermis Market, 2021 - 2033
5.3.3 Mesenchymal Stem Cells
5.3.3.1 Mesenchymal Stem Cells Market, 2021 - 2033
5.3.4 Haematopoietic Stem Cells
5.3.4.1 Haematopoietic Stem Cells Market, 2021 - 2033
5.3.5 Chondrocytes
5.3.5.1 Chondrocytes Market, 2021 - 2033
5.3.6 Others
5.3.6.1 Others Market, 2021 - 2033
Chapter 6 Autologous Cell Therapy Market: Application Analysis
6.1 Autologous Cell Therapy Application Market Share Analysis, 2024 & 2033
6.2 Autologous Cell Therapy Application Market: Segment Dashboard:
6.3 Market Size & Forecasts And Trend Analyses, 2021 To 2033 For The Application Segment
6.3.1 Cancer
6.3.1.1 Cancer Market, 2021 - 2033
6.3.2 Neurodegenerative Disorders
6.3.2.1 Neurodegenerative Disorders Market, 2021 - 2033
6.3.3 Cardiovascular Disorders
6.3.3.1 Cardiovascular Disorders Market, 2021 - 2033
6.3.4 Autoimmune Disorders
6.3.4.1 Autoimmune Disorders Market, 2021 - 2033
6.3.5 Orthopedics
6.3.5.1 Orthopedics Market, 2021 - 2033
6.3.6 Wound Healing
6.3.6.1 Wound Healing Market, 2021 - 2033
6.3.7 Others
6.3.7.1 Others Market, 2021 - 2033
Chapter 7 Autologous Cell Therapy Market: End-Use Analysis
7.1 Autologous Cell Therapy End-Use Market Share Analysis, 2024 & 2033
7.2 Autologous Cell Therapy End-Use Market: Segment Dashboard:
7.3 Market Size & Forecasts And Trend Analyses, 2021 To 2033 For The End-Use Segment
7.3.1 Hospitals & Clinics
7.3.1.1 Hospitals & Clinics Market, 2021 - 2033
7.3.2 Ambulatory Centers
7.3.2.1 Ambulatory Centers Market, 2021 - 2033
7.3.3 Academics & Research
7.3.3.1 Academics & Research Market, 2021 - 2033
7.3.4 Others
7.3.4.1 Others Market, 2021 - 2033
Chapter 8 Autologous Cell Therapy Market: Regional Analysis
8.1 Autologous Cell Therapy Regional Market Share Analysis, 2024 & 2033
8.2 Regional Market Snapshot
8.3 North America
8.3.1 North America Autologous Cell Therapy Market, 2021 - 2033
8.3.2 U.S.
8.3.2.1 U.S. Autologous Cell Therapy Market, 2021 - 2033
8.3.3 Canada
8.3.3.1 Canada Autologous Cell Therapy Market, 2021 - 2033
8.4 Europe
8.4.1 Europe Autologous Cell Therapy Market, 2021 - 2033
8.4.2 U.K.
8.4.2.1 U.K. Autologous Cell Therapy Market, 2021 - 2033
8.4.3 Germany
8.4.3.1 Germany Autologous Cell Therapy Market, 2021 - 2033
8.4.4 France
8.4.4.1 France Autologous Cell Therapy Market, 2021 - 2033
8.4.5 Italy
8.4.5.1 Italy Autologous Cell Therapy Market, 2021 - 2033
8.4.6 Spain
8.4.6.1 Spain Autologous Cell Therapy Market, 2021 - 2033
8.4.7 Russia
8.4.7.1 Russia Autologous Cell Therapy Market, 2021 - 2033
8.5 Asia Pacific
8.5.1 Asia Pacific Autologous Cell Therapy Market, 2021 - 2033
8.5.2 Japan
8.5.2.1 Japan Autologous Cell Therapy Market, 2021 - 2033
8.5.3 China
8.5.3.1 China Autologous Cell Therapy Market, 2021 - 2033
8.5.4 India
8.5.4.1 India Autologous Cell Therapy Market, 2021 - 2033
8.5.5 Australia
8.5.5.1 Australia Autologous Cell Therapy Market, 2021 - 2033
8.5.6 South Korea
8.5.6.1 South Korea Autologous Cell Therapy Market, 2021 - 2033
8.5.7 Singapore
8.5.7.1 Singapore Autologous Cell Therapy Market, 2021 - 2033
8.6 Latin America
8.6.1 Latin America Autologous Cell Therapy Market, 2021 - 2033
8.6.2 Brazil
8.6.2.1 Brazil Autologous Cell Therapy Market, 2021 - 2033
8.6.3 Mexico
8.6.3.1 Mexico Autologous Cell Therapy Market, 2021 - 2033
8.6.4 Argentina
8.6.4.1 Argentina Autologous Cell Therapy Market, 2021 - 2033
8.6.5 Colombia
8.6.5.1 Colombia Autologous Cell Therapy Market, 2021 - 2033
8.7 Middle East And Africa (MEA)
8.7.1 MEA Autologous Cell Therapy Market, 2021 - 2033
8.7.2 South Africa
8.7.2.1 South Africa Autologous Cell Therapy Market, 2021 - 2033
8.7.3 Saudi Arabia
8.7.3.1 Saudi Arabia Autologous Cell Therapy Market, 2021 - 2033
8.7.4 UAE
8.7.4.1 UAE Autologous Cell Therapy Market, 2021 - 2033
Chapter 9 Competitive Analysis
9.1 Recent Developments & Impact Analysis, By Key Market Participants
9.2 Company Profiles
9.2.1 BRAINSTORM CELL THERAPEUTICS INC.
9.2.1.1 Company overview
9.2.1.2 Product benchmarking
9.2.1.3 Strategic initiatives
9.2.2 HOLOSTEM TERAPIE AVANZATE S.R.L
9.2.2.1 Company overview
9.2.2.2 Product benchmarking
9.2.2.3 Strategic initiatives
9.2.3 PHARMICELL CO. INC
9.2.3.1 Company overview
9.2.3.2 Product benchmarking
9.2.4 OPEXA THERAPEUTICS
9.2.4.1 Company overview
9.2.4.2 Product benchmarking
9.2.5 LISATA THERAPEUTIC (CALADRIUS BIOSCIENCES INC)
9.2.5.1 Company overview
9.2.5.2 Product benchmarking
9.2.6 U.S. STEM CELL INC
9.2.6.1 Company overview
9.2.6.2 Product benchmarking
9.2.7 LONZA
9.2.7.1 Company overview
9.2.7.2 Product benchmarking
9.2.7.3 Strategic initiatives
9.2.8 BRISTOL MYERS SQUIBB
9.2.8.1 Company overview
9.2.8.2 Product benchmarking
9.2.8.3 Strategic initiatives
9.2.9 NOVARTIS
9.2.9.1 Company overview
9.2.9.2 Product benchmarking
9.2.9.3 Strategic initiatives
9.2.10 AUTOLUS THERAPEUTICS
9.2.10.1 Company overview
9.2.10.2 Product benchmarking
9.2.10.3 Strategic initiatives
9.2.11 TEGO SCIENCE
9.2.11.1 Company overview
9.2.11.2 Product benchmarking
9.2.11.3 Strategic initiatives
9.2.12 CORNING INCORPORATED
9.2.12.1 Company overview
9.2.12.2 Product benchmarking
9.2.13 BIO ELPIDA
9.2.13.1 Company overview
9.2.13.2 Product benchmarking
9.2.14 VERICEL CORPORATION
9.2.14.1 Company overview
9.2.14.2 Product benchmarking
9.2.15 CATALENT, INC
9.2.15.1 Company overview
9.2.15.2 Product benchmarking
9.2.15.3 Strategic initiatives
9.2.16 SARTORIUS AG
9.2.16.1 Company overview
9.2.16.2 Product benchmarking
9.2.16.3 Strategic initiatives